<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="pmc-domain-id">2103</journal-id><journal-id journal-id-type="pmc-domain">pharmamdpi</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10386689</article-id><article-id pub-id-type="pmcid-ver">PMC10386689.1</article-id><article-id pub-id-type="pmcaid">10386689</article-id><article-id pub-id-type="pmcaiid">10386689</article-id><article-id pub-id-type="pmid">37514045</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics15071859</article-id><article-id pub-id-type="publisher-id">pharmaceutics-15-01859</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Model-Informed Precision Dosing Software Tools for Dosage Regimen Individualization: A Scoping Review</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5986-9198</contrib-id><name name-style="western"><surname>Del Valle-Moreno</surname><given-names initials="P">Paula</given-names></name><xref rid="af1-pharmaceutics-15-01859" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Suarez-Casillas</surname><given-names initials="P">Paloma</given-names></name><xref rid="af1-pharmaceutics-15-01859" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3819-4966</contrib-id><name name-style="western"><surname>Mej&#237;as-Trueba</surname><given-names initials="M">Marta</given-names></name><xref rid="af1-pharmaceutics-15-01859" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-15-01859" ref-type="aff">2</xref><xref rid="c1-pharmaceutics-15-01859" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ciudad-Guti&#233;rrez</surname><given-names initials="P">Pablo</given-names></name><xref rid="af1-pharmaceutics-15-01859" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0882-9254</contrib-id><name name-style="western"><surname>Guisado-Gil</surname><given-names initials="AB">Ana Bel&#233;n</given-names></name><xref rid="af1-pharmaceutics-15-01859" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-15-01859" ref-type="aff">2</xref><xref rid="af3-pharmaceutics-15-01859" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gil-Navarro</surname><given-names initials="MV">Mar&#237;a Victoria</given-names></name><xref rid="af1-pharmaceutics-15-01859" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-15-01859" ref-type="aff">2</xref><xref rid="af3-pharmaceutics-15-01859" ref-type="aff">3</xref><xref rid="fn1-pharmaceutics-15-01859" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2307-944X</contrib-id><name name-style="western"><surname>Herrera-Hidalgo</surname><given-names initials="L">Laura</given-names></name><xref rid="af1-pharmaceutics-15-01859" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-15-01859" ref-type="aff">2</xref><xref rid="fn1-pharmaceutics-15-01859" ref-type="author-notes">&#8224;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Torrado</surname><given-names initials="JJ">Juan Jos&#233;</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-15-01859"><label>1</label>Department of Pharmacy, University Hospital Virgen del Roc&#237;o, 41013 Seville, Spain; <email>pauladelvallem.08@hotmail.com</email> (P.D.V.-M.); <email>palomasuacas@gmail.com</email> (P.S.-C.); <email>pablocg95@gmail.com</email> (P.C.-G.); <email>anaguigil@gmail.com</email> (A.B.G.-G.); <email>mariav.gil.sspa@juntadeandalucia.es</email> (M.V.G.-N.); <email>lauraherrerahidalgo@gmail.com</email> (L.H.-H.)</aff><aff id="af2-pharmaceutics-15-01859"><label>2</label>Department of Infectious Diseases, Microbiology and Parasitology, Infectious Diseases Research Group, Institute of Biomedicine of Seville, University of Seville/Spanish National Research Council/University Hospital Virgen del Rocio, 41013 Seville, Spain</aff><aff id="af3-pharmaceutics-15-01859"><label>3</label>Centre for Biomedical Research Network on Infectious Diseases, 28029 Madrid, Spain</aff><author-notes><corresp id="c1-pharmaceutics-15-01859"><label>*</label>Correspondence: <email>martamejiastrueba@hotmail.com</email></corresp><fn id="fn1-pharmaceutics-15-01859"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>01</day><month>7</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2023</year></pub-date><volume>15</volume><issue>7</issue><issue-id pub-id-type="pmc-issue-id">441865</issue-id><elocation-id>1859</elocation-id><history><date date-type="received"><day>29</day><month>5</month><year>2023</year></date><date date-type="rev-recd"><day>20</day><month>6</month><year>2023</year></date><date date-type="accepted"><day>26</day><month>6</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>07</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>30</day><month>07</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-07-01 00:25:30.177"><day>01</day><month>07</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceutics-15-01859.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="correction-forward" xml:lang="en" xlink:title="correction" vol="16" journal-id="Pharmaceutics" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC11207767"><article-title>Correction: Del Valle-Moreno et al. Model-Informed Precision Dosing Software Tools for Dosage Regimen Individualization: A Scoping Review. <italic toggle="yes">Pharmaceutics</italic> 2023, <italic toggle="yes">15</italic>, 1859</article-title><volume>16</volume><issue>6</issue><date><day>4</day><month>6</month><year>2024</year></date><elocation-id>766</elocation-id><source>Pharmaceutics</source><pub-id pub-id-type="doi">10.3390/pharmaceutics16060766</pub-id><pub-id pub-id-type="pmcid">PMC11207767</pub-id><pub-id pub-id-type="pmid">38931962</pub-id></related-article><abstract><p>Background: Pharmacokinetic nomograms, equations, and software are considered the main tools available for Therapeutic Drug Monitoring (TDM). Model-informed precision dosing (MIPD) is an advanced discipline of TDM that allows dose individualization, and requires a software for knowledge integration and statistical calculations. Due to its precision and extensive applicability, the use of these software is widespread in clinical practice. However, the currently available evidence on these tools remains scarce. Objectives: To review and summarize the available evidence on MIPD software tools to facilitate its identification, evaluation, and selection by users. Methods: An electronic literature search was conducted in MEDLINE, EMBASE, OpenAIRE, and BASE before July 2022. The PRISMA-ScR was applied. The main inclusion criteria were studies focused on developing software for use in clinical practice, research, or modelling. Results: Twenty-eight software were classified as MIPD software. Ten are currently unavailable. The remaining 18 software were described in depth. It is noteworthy that all MIPD software used Bayesian statistical methods to estimate drug exposure and all provided a population model by default, except NONMEN. Conclusions: Pharmacokinetic software have become relevant tools for TDM. MIPD software have been compared, facilitating its selection for use in clinical practice. However, it would be interesting to standardize the quality and validate the software tools.</p></abstract><kwd-group><kwd>model-informed precision dosing</kwd><kwd>software tool</kwd><kwd>therapeutic drug monitoring</kwd></kwd-group><funding-group><award-group><funding-source>Instituto de Salud Carlos III, cofinanced by the European Development Regional Fund (&#8220;A way to achieve Europe&#8221;), Subprograma Juan Rod&#233;s</funding-source><award-id>JR22/00049</award-id><award-id>JR21/00017</award-id></award-group><award-group><funding-source>Instituto de Salud Carlos III, cofinanced by the European Development Regional Fund (&#8220;A way to achieve Europe&#8221;), Subprograma Rio Hortega</funding-source><award-id>CM21/00115</award-id></award-group><funding-statement>The authors received no financial support for the research, authorship, and/or publication of this article. L.H.-H. and A.B.G.-G. were supported by the Instituto de Salud Carlos III, cofinanced by the European Development Regional Fund (&#8220;A way to achieve Europe&#8221;), Subprograma Juan Rod&#233;s (grant JR22/00049 and grant JR21/00017). MMT was supported by the Instituto de Salud Carlos III, cofinanced by the European Development Regional Fund (&#8220;A way to achieve Europe&#8221;), Subprograma Rio Hortega (grant CM21/00115).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-15-01859"><title>1. Introduction</title><p>Clinical pharmacokinetics is a field dedicated to optimizing the dosing regimens of specific medications, aiming to enhance their effectiveness while minimizing undesirable effects in clinical practice [<xref rid="B1-pharmaceutics-15-01859" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-15-01859" ref-type="bibr">2</xref>]. In practical terms, therapeutic drug monitoring (TDM) serves as the application of this discipline in a clinical setting, involving individualized dosing based on tracking drug concentrations. By utilizing this information, dose optimization can be achieved through an assessment of concentration exposure [<xref rid="B3-pharmaceutics-15-01859" ref-type="bibr">3</xref>]. Primary tools employed for TDM include pharmacokinetic (PK) nomograms, equations, and software. Unfortunately, therapeutic failures and toxicities remain prevalent, particularly in medications and populations exhibiting substantial inter- and intraindividual PK variability [<xref rid="B1-pharmaceutics-15-01859" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-15-01859" ref-type="bibr">2</xref>].</p><p>To address this issue, computer programs have been developed to assist professionals in predicting the optimal dosage regimen for individual patients [<xref rid="B1-pharmaceutics-15-01859" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-15-01859" ref-type="bibr">2</xref>]. Model-informed precision dosing (MIPD) represents an advanced discipline within TDM, providing dose individualization primarily based on TDM measurements, and secondarily on PK population models that account for individual characteristics and intra/inter-patient variabilities. The achievement of this approach necessitates the integration of knowledge and mathematical optimization within specialized software [<xref rid="B4-pharmaceutics-15-01859" ref-type="bibr">4</xref>].</p><p>Various software programs have been developed to facilitate predictions of patient drug concentrations and provide dose recommendations that account for individual variations within the population model. These predictions typically rely on the Bayesian theorem [<xref rid="B5-pharmaceutics-15-01859" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-15-01859" ref-type="bibr">6</xref>]. The increasing use of MIPD software can be attributed to its precision, the advancement of population pharmacokinetic models, and the expanding range of drugs that can be optimized. Additionally, there is a growing recognition of the importance of dose individualization for vulnerable populations, including elderly patients, those with renal or hepatic insufficiency, pregnant women, critically ill patients, and pediatric patients. Consequently, computer programs have become highly valued tool sin routine clinical practice [<xref rid="B7-pharmaceutics-15-01859" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-15-01859" ref-type="bibr">8</xref>].</p><p>However, the widespread adoption of MIPD software is hindered by limited accessibility and a lack of comprehensive information about their features and clinical applicability (among other reasons). This lack of information hampers efficient and effective comparative analysis among different software options. Moreover, some authors argue that most pharmacokinetic monitoring software requires further development to enhance user-friendliness, data storage capacity, and report generation [<xref rid="B6-pharmaceutics-15-01859" ref-type="bibr">6</xref>]. Consequently, it is essential to evaluate the current state of software tools.</p><p>The main objective of this scoping review is to identify software specifically designed to support MIPD and provide a comprehensive description of their main features. Special emphasis is given to software intended for use in clinical settings, aiming to assist healthcare professionals in selecting the most suitable software tool to meet their specific needs.</p></sec><sec sec-type="methods" id="sec2-pharmaceutics-15-01859"><title>2. Methods</title><sec id="sec2dot1-pharmaceutics-15-01859"><title>2.1. Protocol and Registration</title><p>A scoping review was performed in accordance with PRISMA-ScR (Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews) guidelines [<xref rid="B9-pharmaceutics-15-01859" ref-type="bibr">9</xref>], and following the protocol published previously [<xref rid="B10-pharmaceutics-15-01859" ref-type="bibr">10</xref>]. The review was registered on the international registry Open Science Framework (ID: 10.17605/OSF.IO/M53NF).</p></sec><sec id="sec2dot2-pharmaceutics-15-01859"><title>2.2. Data Source and Search Strategy</title><p>A literature search was performed in MEDLINE (PubMed) and EMBASE using controlled vocabulary and covering the literature published until 31 July 2022. A complementary search was also conducted in the OpenAIRE and BASE (Bielefeld Academic Search Engine) electronic databases to consult the information published as grey literature. In order to conduct the search and minimize potential publication bias, all the references of the articles found were carefully examined, which made it possible to identify studies that had not been detected during the review. The detailed search strategy is shown in the <xref rid="app1-pharmaceutics-15-01859" ref-type="app">Supplementary Material (Table S1)</xref>.</p></sec><sec id="sec2dot3-pharmaceutics-15-01859"><title>2.3. Articles Eligibility Criteria</title><sec id="sec2dot3dot1-pharmaceutics-15-01859"><title>2.3.1. Inclusion Criteria</title><list list-type="simple"><list-item><label>-</label><p>Studies focused on the design or development of MIPD software tools, as well as studies that provide detailed descriptions on the features of software tools available for use in pharmacokinetics.</p></list-item><list-item><label>-</label><p>Studies including software tools aimed at any medication class.</p></list-item></list></sec><sec id="sec2dot3dot2-pharmaceutics-15-01859"><title>2.3.2. Exclusion Criteria</title><list list-type="simple"><list-item><label>-</label><p>Studies focused on applying an existing software in a patient cohort for TDM without explaining the origin of the development of the software.</p></list-item><list-item><label>-</label><p>Studies that include software that is only available in a particular country.</p></list-item><list-item><label>-</label><p>Articles in a language other than English or Spanish.</p></list-item><list-item><label>-</label><p>Articles not available in full text.</p></list-item></list></sec></sec><sec id="sec2dot4-pharmaceutics-15-01859"><title>2.4. Study Screening and Selection</title><p>Firstly, duplicate articles were eliminated. Thereafter, two reviewers (PVM and PCG) independently selected the articles using the aforementioned inclusion criteria, based on the information obtained from the title and abstract. When in doubt, they read the entire article before deciding whether to include it. Next, the full texts of the articles selected for the reviewers were read and those who met the eligibility criteria were selected. To ensure reproducibility and minimal bias, discrepancies were resolved through discussion and consensus with other reviewers (MMT and LHH). The reasons for the studies&#8217; exclusion were recorded.</p></sec><sec id="sec2dot5-pharmaceutics-15-01859"><title>2.5. Software Selection and Data Collection</title><p>Software designed or suitable for MIPD in the clinical setting were selected and fully described. The software designed for research or for population pharmacokinetic modelling were identified and presented in a table.</p><p>Reviewer PVM independently extracted data, and PSC and MMT examined all extraction sheets to ensure their accuracy. When the software information provided by the studies was insufficient to make an appropriate selection, we conducted an additional search on digital platforms or contacted application developers to request information and guarantee the software met the characteristics described.</p><p>The collected variables were classified into different categories:<list list-type="simple"><list-item><label>(a)</label><p>Focused on the characteristics of the articles included: year and country of publication, aim of studies, and software described.</p></list-item><list-item><label>(b)</label><p>Focused on the characteristics of the identified software:
<list list-type="bullet"><list-item><p>General characteristics:<list list-type="order"><list-item><p>Developer/promoter: the name of the authors, institution, or company participating in software performance.</p></list-item><list-item><p>Year of creation: the year when the first version of the software was created.</p></list-item><list-item><p>Geographical location: the country where the software was developed.</p></list-item><list-item><p>Languages in which the software is available.</p></list-item><list-item><p>Last update of the software.</p></list-item><list-item><p>Use: MIPD, research, or population pharmacokinetic modelling.</p></list-item></list>
</p></list-item><list-item><p>Access options:<list list-type="order"><list-item><p>Possibility of testing the software before contracting it.</p></list-item><list-item><p>Subscription: paid or free access.</p></list-item><list-item><p>Platforms: desktop, web-based, or mobile application.</p></list-item></list>
</p></list-item><list-item><p>Technical characteristics:
<list list-type="order"><list-item><p>Pharmacokinetic analysis type available: Bayesian or non-Bayesian.</p></list-item><list-item><p>Inclusion or not of population data by default: provision or not of a population model created by the software developers.</p></list-item><list-item><p>Possibility of including new drugs and populations by the user or upon request to the developer.</p></list-item><list-item><p>Possibility of issuing reports and creating graphs.</p></list-item><list-item><p>Integration with other systems: Electronic Health Records/Electronic Medical Records (EHR/EMR).</p></list-item></list>
</p></list-item><list-item><p>Potential clinical applicability:<list list-type="order"><list-item><p>Group of drugs classified according to Anatomic Therapeutic Chemical (ATC) code included in the software.</p></list-item><list-item><p>Target population of the models included in the software.</p></list-item><list-item><p>User-friendliness was independely evaluated by two researchers (PVM and LHH).</p></list-item></list>
</p></list-item></list>
</p></list-item></list></p></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-15-01859"><title>3. Results</title><sec id="sec3dot1-pharmaceutics-15-01859"><title>3.1. Literature Search</title><p>A total of 1950 articles were identified in the databases searched (836 in PubMed, 565 in EMBASE, 514 in OpenAIRE, and 35 in BASE) and 4 papers were included after reviewing the literature references. After removing duplicates, a total of 1643 articles remained. Among these, 1227 articles were excluded based on the title and abstract review.</p><p>The remaining 416 studies were considered potentially relevant, and their full texts were retrieved for further examination. From this subset, 391 were excluded before data extraction and 25 met the inclusion criteria (<xref rid="app1-pharmaceutics-15-01859" ref-type="app">Supplementary Figure S1</xref>).</p></sec><sec id="sec3dot2-pharmaceutics-15-01859"><title>3.2. Characteristics of the Articles and Software</title><p>Among the 25 articles included (<xref rid="app1-pharmaceutics-15-01859" ref-type="app">Supplementary Table S2</xref>), 37 software tools were identified.</p><p>The 37 software tools identified were classified: 8 population modelling software, 1 research software, and 28 MIPD software. Additionally, four software were located by manual search: ADAPT, iDose [<xref rid="B11-pharmaceutics-15-01859" ref-type="bibr">11</xref>], RxStudio [<xref rid="B12-pharmaceutics-15-01859" ref-type="bibr">12</xref>], and CAPCIL. The last two programs mentioned are the new versions of ID-ODS and SIMKIN, respectively. <xref rid="app1-pharmaceutics-15-01859" ref-type="app">Supplementary Table S3</xref> shows the software identified and designed for modelling or research.</p><p>During the analysis, a total of 28 MIPD software were thoroughly examined. However, 10 of these software were excluded for various reasons. Five of them were no longer available or marketed (PHAR-MONITOR, PKRD, OPT, DataKineticsTM, and RADKi-netics). Four software were previous versions of other included software, and the newer versions were considered instead (SIMKIN, USC*PACK, T.D.M.S. 2000, and ID-ODS). TDM for R was dismissed as it is a JPKD plugin.</p><p>A full description of the main characteristics of the 18 MIPD software selected are detailed in <xref rid="pharmaceutics-15-01859-t001" ref-type="table">Table 1</xref>. These software were developed between the years 1979 and 2020. Nine of them were developed by commercial companies, while the remaining were created by noncompany providers. Seven software have been updated within the last year. Eleven software offer the option of a free trial, except for NextDose, which does not provide this option. Information regarding free access was not available for the remaining six software. Regarding free access, it is available for four software (JPKD, TCIWorks, TUCUXI, and TDMx). RxStudio and NextDose offer different types of licenses, including paid and free subscriptions with varying functionalities. For instance, the free access to RxStudio only includes simulations of empiric treatments. The access method for CAPCIL is unknown.</p><p>Out of the 18 selected MIPD software, 12 of them are web-based. Among these, four software (Autokinetics, MwPharm, PrecisePK, and RxStudio) also offer a desktop version in addition to the web-based platform. Additionally, DoseMeRx, MwPharm, and RxStudio can also be accessed through mobile applications. The remaining software are solely available in desktop versions.</p><p>All of the MIPD software analyzed in the study employ Bayesian statistical methods to estimate drug exposure and generate dosing recommendations. From a statistical perspective, population PK modelling approaches can be categorized as either parametric or nonparametric [<xref rid="B13-pharmaceutics-15-01859" ref-type="bibr">13</xref>]. In the parametric Bayesian approach, the population parameters are treated as random variables with known prior distributions. Estimating the conditional distribution of the population parameters can be challenging in this case. On the other hand, the nonparametric approach assumes that the population distribution is completely unknown and random, making it a more flexible Bayesian approach [<xref rid="B13-pharmaceutics-15-01859" ref-type="bibr">13</xref>]. It is worth noting that Autokinetics, CAPCIL, and PKS additionally offer the capability to perform linear and nonlinear regression.</p><table-wrap position="anchor" id="pharmaceutics-15-01859-t001" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-01859-t001_Table 1</object-id><label>Table 1</label><caption><p>Descriptive characteristics of the MIPD software.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Autokinetics</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>BESTDOSE</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>CAPCIL</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>DoseMeRx</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>iDose</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>InsightRX Nova</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>JPKD</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Kinetidex</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>MwPharm</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>General characteristics</bold>
</td><td colspan="9" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Developer/<break/>promoter</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paul Elbers, Rob Bosman.<break/>Departments of Intensive Care Medicine of Amsterdam UMC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R.W. Jelliffe. <break/>Laboratory of Applied Pharmaco-kinetics, University of Southern California, LA.<break/>Non-company owners</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Company <break/>(SIMKIN Inc.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Robert McLeay.<break/>DoseMeRx<sup>&#174;</sup> (Tabula Rasa Healthcare Company)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Company (Projections Research Inc. Baysient<sup>&#174;</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sirj Goswami,<break/>Ron Keizer and<break/>Ranvir Mangat.<break/>Company<break/>(Insight Rx Inc.) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">College of Pharmacy, Kaohsiung Medical University (Taiwan)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thomson Reuters corp. (merge between Simkin and Micromedex)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Johannes H. <break/>Proost Department of Pharmacology and Therapeutics, University Centre for Pharmacy, Groningen.<break/>Company (Mediware a.s.)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Year of creation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2006</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1987</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Geographical location</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Netherlands</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Taiwan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Netherlands</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Languages available</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">English</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">English *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">English</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">English</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">English, Dutch, German, French. Possibility of development</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">English *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">English</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">English, Spanish, Dutch, German, Korean, Czech, Portuguese, Japanese, Chinese</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Last update</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Version 2.4.3<break/>Previous version 1973: MM-USC*Pack [<xref rid="B7-pharmaceutics-15-01859" ref-type="bibr">7</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">November 2022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The platform is updated regularly (once a month).<break/>Previous version: InsightRX software [<xref rid="B14-pharmaceutics-15-01859" ref-type="bibr">14</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2008 version 3.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2009<break/>Version 9.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">September 2022<break/>Version 2.2.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Access options</bold>
</td><td colspan="9" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Testing the software</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, a 14-day trial can be generated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subscription</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paid access</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paid access</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paid access</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paid access</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paid access</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Free access</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paid access</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paid access</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Platforms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Desktop and web-based: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.autokinetics.eu">www.autokinetics.eu</uri></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Web-based<break/><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.lapk.org/bestdose.php">www.lapk.org/bestdose.php</uri></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Desktop</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mobile application and web-based: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doseme-rx.com/">https://doseme-rx.com/</uri></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Web-based: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.baysient.net/idose-product/">www.baysient.net/idose-product/</uri></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Web-based: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.insight-rx.com/">www.insight-rx.com/</uri></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Web-based: <uri>pkpd.kmu.edu.tw/jpkd/</uri></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Desktop</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Desktop, mobile application and web-based: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.mediware.cz/">www.mediware.cz/</uri></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Technical characteristics</bold>
</td><td colspan="9" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharmacokinetic analysis type available</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bayesian and non-bayesian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bayesian (non-parametric approach)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bayesian and non-bayesian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bayesian (parametric approach)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bayesian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bayesian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bayesian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bayesian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bayesian (parametric approach)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inclusion/not by default of population data</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, it offers a collection of population PK models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, it offers a collection of population PK models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, it offers a collection of population PK models.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, it offers a collection of population PK models</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inclusion of drugs and populations PK models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, upon request. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, upon request.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, upon request.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, by the user.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, by the user or upon request.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Issuance of reports, creation of graphs </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reports cannot be generated. <break/>Graphical representation can be generated (not exported). </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reports cannot be generated. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reports and graphical representation can be generated. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reports and graphical representation can be generated.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Graphical representation can be generated.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reports and graphical representation can be generated.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reports can be generated.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reports and graphical representation can be generated.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reports and graphical representation can be generated.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Integration into EHR/EMR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes. It can be integrated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes. It can be integrated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes. It can be integrated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes. It can be integrated</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Clinical applicability</bold>
</td><td colspan="9" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug class</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotics, digoxin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotics, digoxin, lidocaine, quinidine, theophylline </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotics, anticoagulants, anticonvulsants antifungals, antineoplastics, antithrombotic, immunosuppressants (drugs for transplants), digoxin, warfarin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunosuppressants (biological agents)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotics, anticoagulants (oral, factors), antifungals, antineoplastics, antipsychotics, antithrombotic, digoxin, immunosuppressants (both drugs for transplants and biological agents), methadone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anticonvulsant, antiepileptic, antivirals, digoxin, immunosuppressants (drugs for transplants), lithium, theophylline, warfarin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotics, antiepileptic, digoxin, theophylline, warfarin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotics, antiepileptics, antihypertensives, antivirals, immunosuppressants (biological agents), digoxin, warfarin</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Target population &#8224;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults, neonates and paediatrics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults, neonates and paediatrics. Haemodialysis and obese</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults and paediatrics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults, neonates and paediatrics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><break/>Adults, neonates and paediatrics. Critically ill patients and haemodialysis<break/></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>NextDose</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>NONMEM</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>PrecisePK</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>PKS</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>RxKinetics</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>RxStudio</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>TCIWorks</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>TUCUXI</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>TDMx</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>General characteristics</bold>
</td><td colspan="9" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Developer/<break/>promoter</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sam Holford<break/>Nick Holford.<break/>University of Auckland<break/>Non-company owned</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Project Group at the University of California, San Francisco<break/>Company (NONMEM<sup>&#174;</sup>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Philip Anderson,<break/>Anjum Gupta.<break/>Company<break/>(Healthware Inc.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Company (Abbott Laboratories, Diagnostic)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">School of Pharmacy and Health Profession, Creighton University</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ajay Gopal,<break/>Gergely Daroczi.<break/>Company (Rx Studio Inc.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">University of Queensland<break/>(Australia) and University of Otago (New Zealand)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yann Thoma.<break/>School of management and engineering of Vaud and the University Hospital of Lausanne </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sebastian Wicha.<break/>Institute of Pharmacy, University of Hamburg</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Year of creation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2012</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1979</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1986</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1991</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1984</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2011</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2013</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Geographical location</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">New Zealand</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">USA/Hungary</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">New Zealand and Australia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Switzerland</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Germany</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Languages available</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">English</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">English</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">English, Spanish, Korean, Chinese, Thai</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">English</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">English</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">English, Spanish, Portuguese, French, Hungarian, and<break/>Simplified Chinese</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">English *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">English</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">German, English</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Last update</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">September 2022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NONMEM 7.5.1<break/>February 2022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">September 2022<break/>Previous version: T.D.M.S.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">November 2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">February 2023. The platform is updated regularly.<break/>Previous version: ID-ODS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">November 2022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">February 2023</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Access options</bold>
</td><td colspan="9" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Testing the software</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, a 30-day trial can be generated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, a 60-day trial version can be downloaded</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subscription</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paid or free access</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paid access</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paid access</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paid access</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paid access</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Paid access. Free individual access for empirical simulations.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Free access</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Free access</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Free access</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Platforms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Web-based: <uri>nextdose.org/</uri></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Desktop</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Desktop and web-based: <uri>precisepk.com/</uri></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Desktop</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Web-based: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.rxkinetics.com/">www.rxkinetics.com/</uri></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Desktop, mobile application, web-based: <uri>rx.studio/</uri></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Desktop</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Desktop</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Web-based: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.tdmx.eu/">www.tdmx.eu/</uri></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Technical characteristics</bold>
</td><td colspan="9" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pharmacokinetic analysis type available</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bayesian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bayesian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bayesian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bayesian and non-bayesian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bayesian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bayesian (parametric approach)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bayesian (parametric approach)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bayesian</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bayesian</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inclusion/not by default of population data</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, it offers a collection of population PK models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No. User may define model for any drug or target population</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, it offers a collection of population PK models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, by the user</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, it offers a collection of population PK models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, it offers a collection of population PK models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, it offers a collection of population PK models</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inclusion of drugs and populations PK models</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, by the user.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, upon request.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, generation of<break/>new drugs in different populations</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, upon request.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, upon request.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, by the user.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, by the user and supported by the developer.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Only new population (not new drugs), implemented by the user.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Issuance of reports, creation of graphs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reports and graphical representation can be generated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reports can be generated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reports can be generated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reports and graphical representation can be generated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reports and graphical representation can be generated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reports and graphical representation can be generated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reports can be generated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reports and graphical representation can be generated.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reports cannot be generated. <break/>Graphical representation can be generated (not exported) </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Integration into EHR/EMR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes. It can be integrated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes. It can be integrated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes. It can be integrated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Clinical applicability</bold>
</td><td colspan="9" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug class</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotics, anticoagulants, antifungals, antineoplastics, antirheumatics, antivirals, immunosuppressants (drugs for transplants), psychostimulant, warfarin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A (selected by the user)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiarrhythmicantiasthmatics, antibiotics, antiepileptics, antifungals, antineoplastics, antipsychotics, immunosuppressants (drugs for transplants)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotics, digoxin, methotrexate, phenytoin, theophylline </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotics, digoxin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotics, antifungals, anticonvulsants, biological agents, immunosuppressants (drugs for transplants), methotrexate, opioids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotics, immunosuppressants (drugs for transplants), theophylline, warfarin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotics, anticoagulants, antivirals, antineoplastics, immunosuppressants (drugs for transplants), kinase inhibitors</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antibiotics, haemostatics (factors), immunosuppressants (biological agents)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Target population &#8224;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults, neonates and paediatrics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults, neonates, paediatrics.<break/>Critically ill patients, obese, renal impairment and haemodialysis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults and paediatrics.<break/>Critically ill patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults and paediatrics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults, neonates and paediatrics. Haemodialysis and haematology patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults and paediatrics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults, neonates and paediatrics</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adults, neonates and paediatrics</td></tr></tbody></table><table-wrap-foot><fn><p>* Availability in other languages unknown. &#8224; At least one model per target population.</p></fn></table-wrap-foot></table-wrap><p>By default, all the MIPD software provide a population model, except for NONMEN, within which models might be defined by users. Thirteen software include models developed for both adult and pediatric populations. Nine software also include models specific to the neonatal population. Moreover, several software tools offer models for special populations: dialysis patients (DoseMeRx, MwPharm, PrecisePK, and RxStudio), obese patients (DoseMeRx and PrecisePK) and critically ill patients (MwPharm, PrecisePK, and PKS). Information regarding this aspect was not available for Autokinetics, BestDose, JPKD, and Kinetidex.</p><p>Among the MIPD software analyzed, there are options for including new population PK models and drugs based on user requests or developer support. Seven software (DoseMeRx, iDose, InsightRX Nova, MwPharm, PrecisePK, RxKinetics, and RxStudio) allow the inclusion of new population PK models and drugs upon user request, while four software (JPKD, MwPharm, NONMEM, and TCIWorks) enable users to add their own models. TUCUXI allows users to include new population PK models and drugs, supported by the developer. TDMx offers the possibility of user-defined new population models but only for the drugs already included by default in the software. InsightRX Nova provides automated population model selection based on patient input data.</p><p>Fifteen MIPD software include the option to generate reports, and ten of them support graphical representation. Integration with EHR is feasible with seven software (Autokinetics, DoseMeRx, InsightRX Nova, MwPharm, PrecisePK, RxStudio, and TUCUXI).</p><p>Regarding the preset drugs accessible in each software, antibiotics are the most commonly implemented drug class. Immunosuppressants are included in eleven software, with specific drugs used in transplant patients such as mTOR inhibitors being included in DoseMeRx, JPKD, NextDose, PrecisePK, RxStudio, TCIWorks, and TUCUXI. Biologic immunomodulator agents are included in iDose, MwPharm, and TDMx. InsightRX Nova covers both transplant drugs and biologics. Antiepileptics are incorporated in four software (JPKD, Kinetidex, MwPharm, and PrecisePK) while kinase inhibitors are only included in TUCUXI. InsightRX Nova covers the most extensive range of drug classes, while Autokinetics and iDose focus on antibiotics and biological agents, respectively. NONMEN does not include any preset drugs, and all drugs must be added by the user.</p><p>Ease-of-use was assessed based on factors such as simple access, a user-friendly interface, and a smooth flow through the necessary steps to perform a simulation. Among the 18 included software, seven were considered intuitive and user-friendly (Tucuxi, PrecisePK, RxStudio, MwPharm, iDose, DoseMe, and InsightRX Nova). All of these software were web-based and had the capability of EHR integration, which enhanced the user experience. They also shared a modern interface where the path to run a simulation was easily identifiable. Four other software (NextDose, BestDose, TDMx, and RxKinetics) were also considered relatively easy to use, although their interfaces were less user-friendly and the workflow was less assisted compared to the previous group. PKS and JPKD were not considered user-friendly due to their outdated interfaces and lack of smooth flow through the screens. NONMEN deserves a special mention as its use requires a high level of expertise not only in pharmacokinetics and pharmacometrics but also in programming, making it less accessible for clinical settings. Lastly, Kinetidex, Autokinetics, CAPCIL, and TCIworks were not accessible to the investigators, so their ease-of-use could not be evaluated.</p></sec></sec><sec sec-type="discussion" id="sec4-pharmaceutics-15-01859"><title>4. Discussion</title><p>This manuscript serves as a scoping review aimed at identifying the MIPD software available globally and providing a comprehensive description of their main features. The objective is to facilitate the selection of the most suitable software for health care professionals in clinical practice.</p><p>Selecting the ideal MIPD software tool can be challenging due to the wide range of available programs and limited accessible information. The lack of information about certain software hinders its potential use in clinical practice, rendering it ineffective. Additionally, locating web-based access to multiple software platforms can be a difficult task.</p><p>Previous nonsystematic studies have explored MIPD software and provided valuable information in the field [<xref rid="B1-pharmaceutics-15-01859" ref-type="bibr">1</xref>,<xref rid="B7-pharmaceutics-15-01859" ref-type="bibr">7</xref>,<xref rid="B14-pharmaceutics-15-01859" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-15-01859" ref-type="bibr">15</xref>]. Buffington et al. conducted a narrative review in 1993, aiming to compare pharmacokinetic software programs and assist clinicians in selecting the most suitable software for their clinical settings [<xref rid="B15-pharmaceutics-15-01859" ref-type="bibr">15</xref>]. They analyzed thirteen software tools, five of which were included in the present scoping review in their updated versions. The remaining eight software tools are no longer commercially available. In 2013, a benchmarking study was conducted [<xref rid="B7-pharmaceutics-15-01859" ref-type="bibr">7</xref>], identifying and analyzing twelve software tools for TDM clinical activities. While all the software mentioned in that study were also included in the present review, two of them (DataKinetics and RADKi-netics) were excluded as they are not currently available. The updated versions of the remaining software tools are described in the present study. A more recent narrative review [<xref rid="B14-pharmaceutics-15-01859" ref-type="bibr">14</xref>] focused on four commercially available MIPD software tools that enable clinicians to apply PK-PD principles to optimize dosing regimens (DoseMeRx, InsightRX, PK-PD Compass, and TDMx). However, the literature search conducted in that study was limited and not systematic, and no benchmarking analysis was performed. Another comparative study in 2020 evaluated the main features and performance of ten MIPD software tools available at that time [<xref rid="B1-pharmaceutics-15-01859" ref-type="bibr">1</xref>]. The results of this study differ from those proposed in 2013 and in the present review, due to the frequent updates and obsolescence of software tools. Having up-to-date information is crucial for selecting the most appropriate software.</p><p>Indeed, comparing the MIPD software tools included in Buffington et al.&#8217;s study [<xref rid="B15-pharmaceutics-15-01859" ref-type="bibr">15</xref>] with the findings of our scoping review highlights the advancements and improvements that have occurred over the years. PrecisePK, formerly known as TDMS, has evolved to become one of the most complete software tools. It now includes features such as a population PK model, report generation capability, and EHR integration, and a wide range of drug classes have been implemented. The ease of manual data entry with PrecisePK was also noted in Kantasiripitak et al. [<xref rid="B1-pharmaceutics-15-01859" ref-type="bibr">1</xref>]. Similarly, USC*PACK, which was recognized as one of the earliest and most widely used clinical pharmacokinetic programs in 1993 [<xref rid="B15-pharmaceutics-15-01859" ref-type="bibr">15</xref>], has undergone transformations and is now represented by the software tool BestDose. Although BestDose may not have ranked among the most attractive software tools based on our analysis, it continues to be utilized in clinical practice.</p><p>One notable difference between the previous studies and our scoping review is the shift towards web-based software tools. The majority of the software tools included in our review, as well as in the recent narrative review, are web-based, offering greater accessibility and ease-of-use. This transition to web-based platforms, coupled with regular updates, reflects the trend towards more sophisticated, user-friendly, and intuitive MIPD software tools that are increasingly utilized by clinicians.</p><p>The implementation of MIPD software has indeed brough about significant advancements in individualized dosage optimization, benefiting both research and clinical practice. These tools have the potential to revolutionize precision dosing by addressing the considerable inter- and intraindividual variability in patient populations, leading to more effective and safer treatment outcomes. In the hospital setting, where patients often have complex conditions and exhibit significant PK alterations, the importance of MIPD software becomes even more pronounced [<xref rid="B16-pharmaceutics-15-01859" ref-type="bibr">16</xref>]. The ability to individualize dosage regimens for a wide range of drugs is crucial in optimizing patient care and achieving desirable therapeutic outcomes. To be effective and widely adopted, MIPD software should possess certain key characteristics. They should be user-friendly, offering simplicity and flexibility in dosage individualization. This means providing the user with the tools and features necessary to tailor doses in various clinical situations, accommodating both simple and complex patient populations. Additionally, ideal software should have data store capability and EHR integration [<xref rid="B1-pharmaceutics-15-01859" ref-type="bibr">1</xref>,<xref rid="B7-pharmaceutics-15-01859" ref-type="bibr">7</xref>,<xref rid="B16-pharmaceutics-15-01859" ref-type="bibr">16</xref>].</p><p>The evaluation of ease-of-use and EHR integration in MIPD software has been a focus of previous studies, providing valuable insights into these important aspects. Fuchs et al. [<xref rid="B7-pharmaceutics-15-01859" ref-type="bibr">7</xref>] emphasized the need for MIPD software tools to evolve towards comprehensive tools with clinical and research capabilities, while maintaining user-friendliness. In their evaluation, MwPharm, MM-USC*PACK (currently BestDose), and TCIWorks were identified as the most sophisticated programs. Similarly, Kantasiripitak et al. [<xref rid="B1-pharmaceutics-15-01859" ref-type="bibr">1</xref>] conducted a user-friendliness evaluation and highlighted DoseMeRx, InsightRX Nova, and MwPharm as meeting the requirements. These software tools were also found to be compatible with her integration. These findings align with our study, where we identified seven out of the eighteen MIPD software as being prepared for EHR integration (Autokinetics, DoseMeRx, InsightRX Nova, MwPharm, PrecisePK, RxStudio, and TUCUXI), making them particularly appealing. The perception of ease-of-use is subjective and influenced by the expertise of the reviewer. However, the agreement between our study&#180;s evaluation and previous findings, particularly regarding the intuitiveness and user-friendliness of web-based software prepared for EHR integration, suggests a consistent understanding of these important features.</p><p>Indeed, the quality of the software, user support services, supported drugs and population models, as well as output generation, are crucial considerations for selecting a MIPD software. The study by Kantasiripitak et al. [<xref rid="B1-pharmaceutics-15-01859" ref-type="bibr">1</xref>] positioned DoseMeRx, InsightRX Nova, and MwPharm as excellent options for dose optimization in clinical practice. Similarly, the review by Fuchs et al. [<xref rid="B7-pharmaceutics-15-01859" ref-type="bibr">7</xref>] identified MwPharm, MM-USC*PACK (currently BestDose), and TCIWorks as the most complete programs. In our opinion, software that includes population PK models for special populations, such as obese patients, critically ill patients, neonates, or patients on dialysis, provides added benefits for professionals who frequently treat patients with more complex requirements. PrecisePK stands out as the most complete tool in this regard, as it includes models for each of the mentioned target populations. Additionally, DoseMeRx, MwPharm, and RxStudio offer the ability to predict optimal dosing regimens for various special populations. Apart from special populations, DoseMeRx, InsightRX Nova, and MwPharm provide the largest collection of population PK models by default. These aspects facilitate the implementation of such software in clinical practice.</p><p>The study acknowledges several limitations that should be taken into consideration. Firstly, the usability of each program was not directly assessed, and there was no testing with real clinical cases of precision dosing. This limitation was due to the potential time constraints of the study. Secondly, feedback from some software developers could not be obtained, which may have affected the completeness of the data. Thirdly, despite carrying out a systematic and well-designed search strategy across numerous databases, consulting grey literature and using MESH terms, it is possible that not all currently available MIPD software tools were detected. This fact reveals the existence of another barrier, which hinders access to software and the application of TDM/MIPD in clinical practice. Additionally, the study did not include a comparison of the accuracy of each program.</p><p>Based on the findings, the authors suggest that information on MIPD software tools should be more accessible to healthcare professionals to facilitate their implementation and promote greater integration into clinical practice. Quality standardization and validation of software tools would be interesting for more accurate selection. Based on the extensive information gathered, DoseMeRx, InsightRx Nova, MwPharm, PrecisePK, and RxStudio are identified as potentially accurate and suitable optimizing dosing regimens in clinical practice. Nevertheless, it is emphasized that software tools should be tested with real patient situations to assess their performance in terms of population and individual patient PK characteristics, accuracy of predictions, and other aspects such as intuitiveness or user-friendliness.</p><p>In conclusion, this scoping review serves as a valuable resource for healthcare professionals by providing relevant information to aid in the selection of MIPD software tools available for routine clinical practice. The review emphasizes the importance of accessibility and availability of information on MIPD software tools to promote their implementation in clinical practice and calls for further standardization, validation, and real-world testing to assess the performance and accuracy of these tools.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to express our gratitude to the software providers who facilitated the information gathering process by providing us with data about their software.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceutics-15-01859"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/pharmaceutics15071859/s1">https://www.mdpi.com/article/10.3390/pharmaceutics15071859/s1</uri>, Figure S1. Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist [<xref rid="B9-pharmaceutics-15-01859" ref-type="bibr">9</xref>]. Table S1. Search strategy. Table S2. Summary of the articles included in this review. Table S3. Software tools for modelling or research. References [<xref rid="B14-pharmaceutics-15-01859" ref-type="bibr">14</xref>,<xref rid="B17-pharmaceutics-15-01859" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-15-01859" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-15-01859" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-15-01859" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceutics-15-01859" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceutics-15-01859" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceutics-15-01859" ref-type="bibr">23</xref>,<xref rid="B24-pharmaceutics-15-01859" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-15-01859" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-15-01859" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceutics-15-01859" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-15-01859" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-15-01859" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-15-01859" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceutics-15-01859" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-15-01859" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-15-01859" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceutics-15-01859" ref-type="bibr">34</xref>,<xref rid="B35-pharmaceutics-15-01859" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-15-01859" ref-type="bibr">36</xref>] are cited in the supplementary materials.</p><supplementary-material id="pharmaceutics-15-01859-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-15-01859-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>P.D.V.-M., P.S.-C. and M.M.-T. participated in data collection and interpretation. P.D.V.-M., M.M.-T. and L.H.-H. participated in writing the paper. P.D.V.-M., M.M.-T., L.H.-H. and M.V.G.-N. participated in the conceptualization and coordination of the study. All authors reviewed and contributed to the final manuscript. All authors have read and agreed to the published version of the manuscript. </p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All data is published in the article or as <xref rid="app1-pharmaceutics-15-01859" ref-type="app">supplementary material</xref>.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-15-01859"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kantasiripitak</surname><given-names>W.</given-names></name><name name-style="western"><surname>Van Daele</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gijsen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ferrante</surname><given-names>M.</given-names></name><name name-style="western"><surname>Spriet</surname><given-names>I.</given-names></name><name name-style="western"><surname>Dreesen</surname><given-names>E.</given-names></name></person-group><article-title>Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?</article-title><source>Front. Pharmacol.</source><year>2020</year><volume>11</volume><fpage>620</fpage><pub-id pub-id-type="doi">10.3389/fphar.2020.00620</pub-id><pub-id pub-id-type="pmid">32457619</pub-id><pub-id pub-id-type="pmcid">PMC7224248</pub-id></element-citation></ref><ref id="B2-pharmaceutics-15-01859"><label>2.</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Dubovitskaya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Buclin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aberer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Thoma</surname><given-names>Y.</given-names></name></person-group><article-title>TUCUXI: An Intelligent System for Personalized Medicine from Individualization of Treatments to Research Databases and Back</article-title><source>Proceedings of the 8th ACM International Conference on Bioinformatics, Computational Biology and Health Informatics&#8212;ACM-BCB &#8216;17</source><conf-loc>Boston, MA, USA</conf-loc><conf-date>20&#8211;23 August 2017</conf-date><comment>Session 8</comment><fpage>223</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1145/3107411.3107439</pub-id></element-citation></ref><ref id="B3-pharmaceutics-15-01859"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mueller-Schoell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Groenland</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Scherf-Clavel</surname><given-names>O.</given-names></name><name name-style="western"><surname>van Dyk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Huisinga</surname><given-names>W.</given-names></name><name name-style="western"><surname>Michelet</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jaehde</surname><given-names>U.</given-names></name><name name-style="western"><surname>Steeghs</surname><given-names>N.</given-names></name><name name-style="western"><surname>Huitema</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Kloft</surname><given-names>C.</given-names></name></person-group><article-title>Therapeutic drug monitoring of oral targeted antineoplastic drugs</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2021</year><volume>77</volume><fpage>441</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1007/s00228-020-03014-8</pub-id><pub-id pub-id-type="pmid">33165648</pub-id><pub-id pub-id-type="pmcid">PMC7935845</pub-id></element-citation></ref><ref id="B4-pharmaceutics-15-01859"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>P&#233;rez-Blanco</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Lanao</surname><given-names>J.M.</given-names></name></person-group><article-title>Model-Informed Precision Dosing (MIPD)</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>2731</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14122731</pub-id><pub-id pub-id-type="pmid">36559225</pub-id><pub-id pub-id-type="pmcid">PMC9780803</pub-id></element-citation></ref><ref id="B5-pharmaceutics-15-01859"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pai</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Neely</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rodvold</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Lodise</surname><given-names>T.P.</given-names></name></person-group><article-title>Innovative approaches to optimizing the delivery of vancomycin in individual patients</article-title><source>Adv. Drug Deliv. Rev.</source><year>2014</year><volume>77</volume><fpage>50</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2014.05.016</pub-id><pub-id pub-id-type="pmid">24910345</pub-id></element-citation></ref><ref id="B6-pharmaceutics-15-01859"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Messori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bosi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guidi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Longo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pistolesi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Saccardi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Valenza</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vannucchi</surname><given-names>A.</given-names></name></person-group><article-title>PKRD: A pharmacokinetic program for least-squares and bayesian analysis of repeated-dose pharmacokinetic curves</article-title><source>Comput. Methods Programs Biomed.</source><year>1992</year><volume>38</volume><fpage>27</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/0169-2607(92)90072-F</pub-id><pub-id pub-id-type="pmid">1473336</pub-id></element-citation></ref><ref id="B7-pharmaceutics-15-01859"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fuchs</surname><given-names>A.</given-names></name><name name-style="western"><surname>Csajka</surname><given-names>C.</given-names></name><name name-style="western"><surname>Thoma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Buclin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Widmer</surname><given-names>N.</given-names></name></person-group><article-title>Benchmarking Therapeutic Drug Monitoring Software: A Review of Available Computer Tools</article-title><source>Clin. Pharmacokinet.</source><year>2013</year><volume>52</volume><fpage>9</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1007/s40262-012-0020-y</pub-id><pub-id pub-id-type="pmid">23196713</pub-id></element-citation></ref><ref id="B8-pharmaceutics-15-01859"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Velde</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mouton</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>de Winter</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>van Gelder</surname><given-names>T.</given-names></name><name name-style="western"><surname>Koch</surname><given-names>B.</given-names></name></person-group><article-title>Clinical applications of population pharmacokinetic models of antibiotics: Challenges and perspectives</article-title><source>Pharmacol. Res.</source><year>2018</year><volume>134</volume><fpage>280</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2018.07.005</pub-id><pub-id pub-id-type="pmid">30033398</pub-id></element-citation></ref><ref id="B9-pharmaceutics-15-01859"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tricco</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Lillie</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zarin</surname><given-names>W.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Colquhoun</surname><given-names>H.</given-names></name><name name-style="western"><surname>Levac</surname><given-names>D.</given-names></name><name name-style="western"><surname>Moher</surname><given-names>D.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>M.D.J.</given-names></name><name name-style="western"><surname>Horsley</surname><given-names>T.</given-names></name><name name-style="western"><surname>Weeks</surname><given-names>L.</given-names></name><etal/></person-group><article-title>PRISMA Extension for Scoping Reviews (PRISMAScR): Checklist and Explanation</article-title><source>Ann. Intern. Med.</source><year>2018</year><volume>169</volume><fpage>467</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.7326/M18-0850</pub-id><pub-id pub-id-type="pmid">30178033</pub-id></element-citation></ref><ref id="B10-pharmaceutics-15-01859"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Valle-Moreno</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ciudad-Guti&#233;rrez</surname><given-names>P.</given-names></name><name name-style="western"><surname>Herrera-Hidalgo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guisado-Gil</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Gil-Navarro</surname><given-names>M.V.</given-names></name></person-group><article-title>Pharmacokinetic software for therapeutic drug monitoring: A scoping review protocol</article-title><source>Farm Hosp.</source><year>2021</year><volume>45</volume><fpage>109</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">35379117</pub-id></element-citation></ref><ref id="B11-pharmaceutics-15-01859"><label>11.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Baysient LLC</collab></person-group><article-title>iDose<sup>&#174;</sup> and T3 Time to Target<sup>&#174;</sup>. USA</article-title><year>2023</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.baysient.net/" ext-link-type="uri">https://www.baysient.net/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-20">(accessed on 20 April 2023)</date-in-citation></element-citation></ref><ref id="B12-pharmaceutics-15-01859"><label>12.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Rx Studio Inc</collab></person-group><article-title>USA/Hungary; 2022&#8211;2023</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://rx.studio/" ext-link-type="uri">https://rx.studio/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-04-20">(accessed on 20 April 2023)</date-in-citation></element-citation></ref><ref id="B13-pharmaceutics-15-01859"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tatarinova</surname><given-names>T.</given-names></name><name name-style="western"><surname>Neely</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bartroff</surname><given-names>J.</given-names></name><name name-style="western"><surname>van Guilder</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bayard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jelliffe</surname><given-names>R.</given-names></name><name name-style="western"><surname>Leary</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chubatiuk</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schumitzky</surname><given-names>A.</given-names></name></person-group><article-title>Two general methods for population pharmacokinetic modeling: Non-parametric adaptive grid and non-parametric Bayesian</article-title><source>J. Pharmacokinet. Pharmacodyn.</source><year>2013</year><volume>40</volume><fpage>189</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1007/s10928-013-9302-8</pub-id><pub-id pub-id-type="pmid">23404393</pub-id><pub-id pub-id-type="pmcid">PMC3630269</pub-id></element-citation></ref><ref id="B14-pharmaceutics-15-01859"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Owens</surname><given-names>R.C.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Bulik</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Andes</surname><given-names>D.R.</given-names></name></person-group><article-title>Pharmacokinetics-pharmacodynamics, computer decision support technologies, and antimicrobial stewardship: The compass and rudder</article-title><source>Diagn. Microbiol. Infect. Dis.</source><year>2018</year><volume>91</volume><fpage>371</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/j.diagmicrobio.2018.03.015</pub-id><pub-id pub-id-type="pmid">29776710</pub-id></element-citation></ref><ref id="B15-pharmaceutics-15-01859"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buffington</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Lampasona</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chandler</surname><given-names>M.H.</given-names></name></person-group><article-title>Computers in pharmacokinetics. Choosing software for clinical decision making</article-title><source>Clin. Pharmacokinet.</source><year>1993</year><volume>25</volume><fpage>205</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.2165/00003088-199325030-00004</pub-id><pub-id pub-id-type="pmid">8222461</pub-id></element-citation></ref><ref id="B16-pharmaceutics-15-01859"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jager</surname><given-names>N.G.L.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>van Hest</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Lipman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Cotta</surname><given-names>M.O.</given-names></name></person-group><article-title>Precision dosing software to optimize antimicrobial dosing: A systematic search and follow-up survey of available programs</article-title><source>Clin. Microbiol. Infect.</source><year>2022</year><volume>28</volume><fpage>1211</fpage><lpage>1224</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2022.03.041</pub-id><pub-id pub-id-type="pmid">35429656</pub-id></element-citation></ref><ref id="B17-pharmaceutics-15-01859"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatton</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Massey</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>W.L.</given-names></name></person-group><article-title>Comparison of the Predictions of One- and Two-Compartment Microcomputer Programs for Long-Term Tobramycin Therapy</article-title><source>Ther. Drug Monit.</source><year>1984</year><volume>6</volume><fpage>432</fpage><lpage>437</lpage><pub-id pub-id-type="doi">10.1097/00007691-198412000-00009</pub-id><pub-id pub-id-type="pmid">6549085</pub-id></element-citation></ref><ref id="B18-pharmaceutics-15-01859"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deci</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Grauer</surname><given-names>K.</given-names></name></person-group><article-title>Computer Prediction of Serum Theophylline Concentrations in Ambulatory Patients</article-title><source>Ther. Drug Monit.</source><year>1985</year><volume>7</volume><fpage>421</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1097/00007691-198512000-00010</pub-id><pub-id pub-id-type="pmid">3841237</pub-id></element-citation></ref><ref id="B19-pharmaceutics-15-01859"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leal</surname><given-names>T.</given-names></name><name name-style="western"><surname>Parez</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Vanbinst</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wallemacq</surname><given-names>P.E.</given-names></name></person-group><article-title>Computerized approach to monitoring aminoglycosides</article-title><source>Clin. Chem.</source><year>1991</year><volume>37</volume><fpage>1415</fpage><lpage>1419</lpage><pub-id pub-id-type="doi">10.1093/clinchem/37.8.1415</pub-id><pub-id pub-id-type="pmid">1868604</pub-id></element-citation></ref><ref id="B20-pharmaceutics-15-01859"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Proost</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Meijer</surname><given-names>D.K.</given-names></name></person-group><article-title>MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring</article-title><source>Comput. Biol. Med.</source><year>1992</year><volume>22</volume><fpage>155</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/0010-4825(92)90011-B</pub-id><pub-id pub-id-type="pmid">1617949</pub-id></element-citation></ref><ref id="B21-pharmaceutics-15-01859"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gill</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Okamoto</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Nakahiro</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Chin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Inagaki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sclar</surname><given-names>D.A.</given-names></name></person-group><article-title>Pharmacokinetic population parameters for aminoglycosides in cholecystitis patients</article-title><source>Ther. Drug Monit.</source><year>1992</year><volume>14</volume><fpage>107</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1097/00007691-199204000-00005</pub-id><pub-id pub-id-type="pmid">1585393</pub-id></element-citation></ref><ref id="B22-pharmaceutics-15-01859"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McMichael</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lieberman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Doyle</surname><given-names>H.</given-names></name><name name-style="western"><surname>McCauley</surname><given-names>J.</given-names></name><name name-style="western"><surname>van Thiel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fung</surname><given-names>J.</given-names></name><name name-style="western"><surname>Starzl</surname><given-names>T.E.</given-names></name></person-group><article-title>Computer-guided concentration-controlled trials in autoimmune disorders</article-title><source>Ther. Drug Monit.</source><year>1993</year><volume>15</volume><fpage>510</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1097/00007691-199312000-00010</pub-id><pub-id pub-id-type="pmid">7510078</pub-id></element-citation></ref><ref id="B23-pharmaceutics-15-01859"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ismail</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>A.F.A.</given-names></name></person-group><article-title>Estimation of population pharmacokinetics for carbamazepine in Malaysian patients using the OPT<sup>&#174;</sup> computer program</article-title><source>J. Clin. Pharm. Ther.</source><year>1993</year><volume>18</volume><fpage>55</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2710.1993.tb00567.x</pub-id><pub-id pub-id-type="pmid">8473361</pub-id></element-citation></ref><ref id="B24-pharmaceutics-15-01859"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lacarelle</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pisano</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>T.</given-names></name><name name-style="western"><surname>Villard</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Guder</surname><given-names>F.</given-names></name><name name-style="western"><surname>Catalin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Durand</surname><given-names>A.</given-names></name></person-group><article-title>Abbott PKS system: A new version for applied pharmacokinetics including Bayesian estimation</article-title><source>Int. J. Bio-Med. Comput.</source><year>1994</year><volume>36</volume><fpage>127</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/0020-7101(94)90103-1</pub-id><pub-id pub-id-type="pmid">7927851</pub-id></element-citation></ref><ref id="B25-pharmaceutics-15-01859"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jerling</surname><given-names>M.</given-names></name></person-group><article-title>Population pharmacokinetics and pharmacodynamics: Potential use for gathering dose-concentration-response</article-title><source>Eur. J. Drug Metab. Pharmacokinet.</source><year>1996</year><volume>21</volume><fpage>113</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1007/BF03190259</pub-id><pub-id pub-id-type="pmid">8839684</pub-id></element-citation></ref><ref id="B26-pharmaceutics-15-01859"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falc&#227;o</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Rocha</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Caramona</surname><given-names>M.M.</given-names></name></person-group><article-title>Theophylline pharmacokinetics with concomitant steroid and gold therapy</article-title><source>J. Clin. Pharm. Ther.</source><year>2000</year><volume>25</volume><fpage>191</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2710.2000.00279.x</pub-id><pub-id pub-id-type="pmid">10886464</pub-id></element-citation></ref><ref id="B27-pharmaceutics-15-01859"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Duffull</surname><given-names>S.B.</given-names></name></person-group><article-title>Development of a bayesian forecasting method for warfarin dose individualization</article-title><source>Pharm. Res.</source><year>2011</year><volume>28</volume><fpage>1100</fpage><lpage>1111</lpage><pub-id pub-id-type="doi">10.1007/s11095-011-0369-x</pub-id><pub-id pub-id-type="pmid">21301936</pub-id></element-citation></ref><ref id="B28-pharmaceutics-15-01859"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neely</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>van Guilder</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Schumitzky</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jelliffe</surname><given-names>R.W.</given-names></name></person-group><article-title>Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R</article-title><source>Ther. Drug Monit.</source><year>2012</year><volume>34</volume><fpage>467</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1097/FTD.0b013e31825c4ba6</pub-id><pub-id pub-id-type="pmid">22722776</pub-id><pub-id pub-id-type="pmcid">PMC3394880</pub-id></element-citation></ref><ref id="B29-pharmaceutics-15-01859"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Felton</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Lodise</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Van Guilder</surname><given-names>M.</given-names></name><name name-style="western"><surname>Boselli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Neely</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Hope</surname><given-names>W.W.</given-names></name></person-group><article-title>Individualization of piperacillin dosing for critically ill patients: Dosing software to optimize antimicrobial therapy</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>4094</fpage><lpage>4102</lpage><pub-id pub-id-type="doi">10.1128/AAC.02664-14</pub-id><pub-id pub-id-type="pmid">24798288</pub-id><pub-id pub-id-type="pmcid">PMC4068511</pub-id></element-citation></ref><ref id="B30-pharmaceutics-15-01859"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nugroho</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Lukman</surname><given-names>H.</given-names></name></person-group><article-title>The capability of Several Population-based Approach Software to Analyze Sparse Drug Plasma Concentration Data after Intra-Venous Bolus Injection</article-title><source>Indones. J. Pharm.</source><year>2019</year><volume>30</volume><fpage>293</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.14499/indonesianjpharm30iss4pp293</pub-id></element-citation></ref><ref id="B31-pharmaceutics-15-01859"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okour</surname><given-names>M.</given-names></name></person-group><article-title>DosePredict: A Shiny Application for Generalized Pharmacokinetics-Based Dose Predictions</article-title><source>J. Clin. Pharmacol.</source><year>2020</year><volume>60</volume><fpage>1502</fpage><lpage>1508</lpage><pub-id pub-id-type="doi">10.1002/jcph.1649</pub-id><pub-id pub-id-type="pmid">32542731</pub-id></element-citation></ref><ref id="B32-pharmaceutics-15-01859"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Porub&#228;n</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ko&#345;&#237;stkov&#225;</surname><given-names>B.</given-names></name><name name-style="western"><surname>Grundmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kac&#237;&#345;ov&#225;</surname><given-names>I.</given-names></name></person-group><article-title>Comparison of DOS and Windows version of the MwPharm&#8212;A pharmacokinetic software for PK/PD monitoring of digoxin</article-title><source>Klin. Farmakol. Farm.</source><year>2020</year><volume>34</volume><fpage>152</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.36290/far.2020.026</pub-id></element-citation></ref><ref id="B33-pharmaceutics-15-01859"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ryan</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Carland</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>McLeay</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marriott</surname><given-names>D.J.E.</given-names></name><name name-style="western"><surname>Day</surname><given-names>R.O.</given-names></name><name name-style="western"><surname>Stocker</surname><given-names>S.L.</given-names></name></person-group><article-title>Evaluation of amikacin use and comparison of the models implemented in two Bayesian forecasting software packages to guide dosing</article-title><source>Br. J. Clin. Pharmacol.</source><year>2021</year><volume>87</volume><fpage>1422</fpage><lpage>1431</lpage><pub-id pub-id-type="doi">10.1111/bcp.14542</pub-id><pub-id pub-id-type="pmid">32881037</pub-id></element-citation></ref><ref id="B34-pharmaceutics-15-01859"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dave</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Dherai</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Mould</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Ashavaid</surname><given-names>T.F.</given-names></name></person-group><article-title>Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience</article-title><source>Eur. J. Clin. Pharmacol.</source><year>2021</year><volume>77</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1007/s00228-020-02975-0</pub-id><pub-id pub-id-type="pmid">32803288</pub-id></element-citation></ref><ref id="B35-pharmaceutics-15-01859"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sturkenboom</surname><given-names>M.G.G.</given-names></name><name name-style="western"><surname>M&#228;rtson</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Svensson</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Sloan</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Dooley</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>van den Elsen</surname><given-names>S.H.J.</given-names></name><name name-style="western"><surname>Denti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Peloquin</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Aarnoutse</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Alffenaar</surname><given-names>J.C.</given-names></name></person-group><article-title>Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs</article-title><source>Clin. Pharmacokinet.</source><year>2021</year><volume>60</volume><fpage>685</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1007/s40262-021-00997-0</pub-id><pub-id pub-id-type="pmid">33674941</pub-id><pub-id pub-id-type="pmcid">PMC7935699</pub-id></element-citation></ref><ref id="B36-pharmaceutics-15-01859"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heitzmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thoma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bricca</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gagnieu</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Leclerc</surname><given-names>V.</given-names></name><name name-style="western"><surname>Roux</surname><given-names>S.</given-names></name><name name-style="western"><surname>Conrad</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferry</surname><given-names>T.</given-names></name><name name-style="western"><surname>Goutelle</surname><given-names>S.</given-names></name></person-group><article-title>Implementation and Comparison of Two Pharmacometric Tools for Model-Based Therapeutic Drug Monitoring and Precision Dosing of Daptomycin</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>114</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14010114</pub-id><pub-id pub-id-type="pmid">35057009</pub-id><pub-id pub-id-type="pmcid">PMC8779485</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>